153 related articles for article (PubMed ID: 25457814)
1. Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey.
Wang V; Chao TH; Hsieh CC; Lin CC; Kao CH
Parkinsonism Relat Disord; 2015 Jan; 21(1):18-22. PubMed ID: 25457814
[TBL] [Abstract][Full Text] [Related]
2. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.
Trifirò G; Mokhles MM; Dieleman JP; van Soest EM; Verhamme K; Mazzaglia G; Herings R; de Luise C; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; van Camp G; Zanettini R; Sturkenboom MC
Drug Saf; 2012 Feb; 35(2):159-71. PubMed ID: 22204718
[TBL] [Abstract][Full Text] [Related]
4. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
[TBL] [Abstract][Full Text] [Related]
5. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Grosset K; Needleman F; Macphee G; Grosset D
Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
[TBL] [Abstract][Full Text] [Related]
6. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
7. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
Tran T; Brophy JM; Suissa S; Renoux C
CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
[TBL] [Abstract][Full Text] [Related]
8. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
9. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
11. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease.
Antonini A; Tolosa E; Mizuno Y; Yamamoto M; Poewe WH
Lancet Neurol; 2009 Oct; 8(10):929-37. PubMed ID: 19709931
[TBL] [Abstract][Full Text] [Related]
12. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
14. Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease.
Stocchi F; Fossati B; Torti M
Expert Opin Drug Saf; 2020 Sep; 19(9):1155-1172. PubMed ID: 32869676
[TBL] [Abstract][Full Text] [Related]
15. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
[TBL] [Abstract][Full Text] [Related]
16. Risk of heart failure associated with dopamine agonists: a nested case-control study.
Hsieh PH; Hsiao FY
Drugs Aging; 2013 Sep; 30(9):739-45. PubMed ID: 23881697
[TBL] [Abstract][Full Text] [Related]
17. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.
Montastruc F; Moulis F; Araujo M; Chebane L; Rascol O; Montastruc JL
Eur J Clin Pharmacol; 2017 Jan; 73(1):99-103. PubMed ID: 27796464
[TBL] [Abstract][Full Text] [Related]
18. [Valvular heart disease associated with the treatment of Parkinson disease].
Rasmussen VG; Dupont E; Østergaard K; Egeblad H
Ugeskr Laeger; 2006 Jun; 168(26-32):2542-4. PubMed ID: 16824407
[TBL] [Abstract][Full Text] [Related]
19. Combination of two different dopamine agonists in the management of Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
[TBL] [Abstract][Full Text] [Related]
20. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Razmy A; Lang AE; Shapiro CM
Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
